Tilvestamab
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas[1].
Product Specifications
CAS Number
[2226775-26-2]
Product Name Alternative
BGB149
UNSPSC
12352203
Target
TAM Receptor
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tilvestamab.html
Purity
98.08
Solubility
10 mM in DMSO
Smiles
[Tilvestamab]
Molecular Weight
(146.16 kDa)
References & Citations
[1]Chen TJ, et al. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model. Physiol Rep. 2021 Dec;9 (23) :e15140.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Isoform
Axl
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6009457-01 0.2 mL
HSPC142, NT (BABAM1, C19orf62, MERIT40, NBA1, BRISC and BRCA1-A complex member 1, Mediator of RAP80 interactions and targeting subunit of 40kD, New component of the BRCA1-A complex)
Ask
View Details 
MBS6009457-02 5x 0.2 mL
HSPC142, NT (BABAM1, C19orf62, MERIT40, NBA1, BRISC and BRCA1-A complex member 1, Mediator of RAP80 interactions and targeting subunit of 40kD, New component of the BRCA1-A complex)
Ask
View Details 